What is the maximum recommended dose of domperidone (per day) for a patient with gastrointestinal motility disorders or nausea and vomiting?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Recommended Dose of Domperidone

The maximum daily dose of domperidone is 30 mg per day, with treatment duration limited to 7 days for nausea and vomiting, as mandated by regulatory authorities due to cardiac safety concerns. 1

Regulatory Restrictions and Safety Basis

  • Following a 2014 safety review, the European Medicines Agency restricted domperidone to a maximum daily dose of 30 mg and limited treatment duration to 7 days specifically for nausea and vomiting. 1, 2

  • The National Patient Safety Agency (NPSA) issued alerts highlighting QTc prolongation risks with domperidone, requiring QTc monitoring for long-term use. 3

  • These restrictions were implemented despite controversial evidence, as the definitive link between domperidone and sudden cardiac death remains debated in the literature. 2

Dosing in Gastrointestinal Motility Disorders

  • For gastroparesis and chronic gastrointestinal motility disorders, domperidone is generally not recommended for long-term use under current regulatory guidance. 3

  • The European Medicines Agency's Committee specifically recommends against long-term use of domperidone due to lack of consistent benefit in gastroparesis and cardiac safety concerns. 3

  • When domperidone must be used beyond acute indications, doses above 30 mg daily should only be considered with extreme caution, particularly in patients over 60 years of age. 4

Clinical Context and Monitoring

  • In specialized settings with FDA investigational protocols, doses up to 120 mg/day have been studied for refractory gastroparesis, but this requires intensive cardiac monitoring with frequent ECGs and is not standard practice. 5

  • A retrospective study of high-dose domperidone (40-120 mg/day) found that 9.5% of patients experienced asymptomatic QTc prolongation >450 ms (males) or >470 ms (females), though no patients reached the critical threshold of >500 ms. 5

  • Standard monitoring at conventional doses (30-80 mg/day) showed only 6% of patients developed clinically important QTc prolongation, with none exceeding 500 ms. 6

Common Pitfalls to Avoid

  • Do not prescribe domperidone as repeat prescriptions beyond 7 days without specific justification and cardiac monitoring, as this violates regulatory guidance and increases risk. 1

  • Avoid domperidone in patients with pre-existing cardiac conditions, electrolyte disturbances, or those taking other QTc-prolonging medications, as these significantly increase arrhythmia risk. 5

  • Do not use domperidone doses exceeding 30 mg/day in routine clinical practice outside of specialized investigational protocols with appropriate monitoring. 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.